RedHill Biopharma Ltd – ADR (RDHL) GI Topline Is Set For 2016 Release

RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) just informed markets that it intends to put out topline data from its phase III trial of Bekinda in a gastroenteritis indication.

Keep Reading →